-
Sector Analysis
Coronary Stents Market Size by Segments, Share, Regulatory, Reimbursement, Procedures and Forecast to 2033
Coronary Stents Market Overview The coronary stents market size was valued at $4.37 billion in 2023. The market will grow at a CAGR of less than 1% during 2023-2033. Factors such as rapidly changing lifestyles and growing unhealthy diets are leading to increased risk of coronary heart disease, which will drive the market growth in coming years. A coronary stent is an expandable perforated tube that is inserted into a natural conduit of the body to prevent or counteract a...
-
Product Insights
Net Present Value Model: Lepu Biopharma Co Ltd’s MRG-002
Empower your strategies with our Net Present Value Model: Lepu Biopharma Co Ltd's MRG-002 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Insights
Innovation and Patenting activity of Lepu Medical Technology (Beijing) Co Ltd Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Lepu Medical Technology (Beijing) Co Ltd Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pucotenlimab in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pucotenlimab in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pucotenlimab in Non-Small Cell Lung Cancer Drug Details: Pucotenlimab (Puyouheng)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Orelabrutinib in Relapsed Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Orelabrutinib in Relapsed Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Orelabrutinib in Relapsed Chronic Lymphocytic Leukemia (CLL) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pucotenlimab in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pucotenlimab in Metastatic Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pucotenlimab in Metastatic Colorectal Cancer Drug Details: Pucotenlimab (Puyouheng) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pucotenlimab in Hepatocellular Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pucotenlimab in Hepatocellular Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pucotenlimab in Hepatocellular Carcinoma Drug Details: Pucotenlimab (Puyouheng) is a humanized...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pucotenlimab in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pucotenlimab in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pucotenlimab in Triple-Negative Breast Cancer (TNBC) Drug Details: Pucotenlimab...
-
Sector Analysis
Prosthetic Heart Valves Market Size by Segments, Share, Regulatory, Reimbursement, Procedures and Forecast to 2033
Prosthetic Heart Valves Market Report Overview The prosthetic heart valves market size was valued at $2.15 billion in 2023. The prosthetic heart valves market will grow at a CAGR of more than 3% from 2023 to 2033. The growing aging population across the globe and the associated valvular degeneration is primarily driving the prosthetic heart valve market growth. Prosthetic Heart Valves Market Outlook 2023-2033 ($ Billion) Buy the Full Report for More Insights on the Prosthetic Heart Valves Market Forecast,...